Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A use of shikonian acid for reversing drug resistance of ovarian cancer to paclitaxel

A technology for ovarian cancer and drug resistance, applied in the field of medicine, can solve the problems of high mortality and high recurrence rate of the disease

Active Publication Date: 2020-12-18
菅金波
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the drug resistance of ovarian cancer cells to chemotherapy drugs leads to a high recurrence rate and high mortality rate of the disease, which has become a bottleneck in clinical treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A use of shikonian acid for reversing drug resistance of ovarian cancer to paclitaxel
  • A use of shikonian acid for reversing drug resistance of ovarian cancer to paclitaxel

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The substantive content of the present invention will be described in detail below in conjunction with the embodiments, but the protection scope of the present invention is not limited thereto.

[0014] 1. Experimental materials

[0015] Comfrey acid, comfrey alkyd, cedarwood acid and cedarwood alcohol are self-made, the purity is ≥98%, and the structural formula is as follows figure 1 shown. Paclitaxel (Taxol) was purchased from Xi'an Kangnuo Chemical Co., Ltd., with a purity of ≥98%. Dimethyl sulfoxide (DMSO) was purchased from Sigma. Tetramethylthiazole light blue (MTT) was purchased from Biyuntian Biotechnology Research Institute.

[0016] Fetal bovine serum and DMEM medium were purchased from Gibco.

[0017] Human ovarian cancer paclitaxel-resistant cell line A2780 / Taxol was purchased from Shanghai Meixuan Biotechnology Co., Ltd.

[0018] 2. Experimental method

[0019] 1. Cell culture

[0020] DMEM medium containing 10% fetal bovine serum at 37°C, 5% CO 2 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses use of lacca acid in reversing paclitaxel medical resistance in ovarian cancer. Ovarian cancer is one of the three major malignant tumors of female reproductive system, and thesurvival time of most patients with advanced ovarian cancer is less than 5 years. Clinical treatment of ovarian cancer usually uses cytoreductive surgery and postoperative chemotherapy with platinumand paclitaxel. However, ovarian cancer cell resistance to chemotherapy drugs leads to high recurrence rate and mortality, so it becomes the bottleneck of clinical treatment. The invention discloses that lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees, improve the sensitivity of cells to Taxol, and canbe developed as a medicine for reversing the resistance of ovarian cancer to taxol. The invention is characterized in that the lacca acid, lacca acid alkyd and cedric acid can enhance the proliferation inhibition effect of Taxol on A2780 / Taxol cells in different degrees and improve the sensitivity of cells to Taxol.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the discovery of drugs for reversing drug resistance of ovarian cancer to paclitaxel. Background technique [0002] Ovarian cancer is one of the three major malignant tumors of the female reproductive system, and the survival time of most advanced ovarian cancer patients is less than 5 years. The clinical treatment of ovarian cancer usually uses tumor cytoreductive surgery, supplemented by chemotherapy with platinum and paclitaxel after surgery. However, the drug resistance of ovarian cancer cells to chemotherapeutic drugs leads to a high recurrence rate and high mortality rate of the disease, which has become a bottleneck in clinical treatment. Contents of the invention [0003] The purpose of the present invention is to provide a drug for reversing drug resistance of ovarian cancer to paclitaxel. [0004] The present invention realizes through following technical scheme: [0005] Appl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/19A61K31/045A61P35/00
CPCA61K31/045A61K31/19A61P35/00
Inventor 菅金波张鲁燕李娟娟郑嘉荣区伟平万超
Owner 菅金波
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com